Market Definition 

Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, that attacks the body's immune system and can be transferred from one person to another through blood and sexual contact. HIV drugs help to prevent the multiplication of HIV virus and reduce the risk of its transmission. 

Global HIV drugs market is estimated to reach $XX billion by 2027, growing at a CAGR of 4.1% till 2027. 

Market Dynamics 

The rising prevalence and number of HIV cases globally is boosting the market growth. For instance, according to U.S. Department of Health & Human Services and supported, approximately 38 million people around the globe with HIV/AIDS in 2019. Of which, 36.2 million were adults and 1.8 million were children. According to U.S. Department of Health & Human Services and supported, around 1.2 million people in the U.S. are living with HIV in 2020. According to the Pan American Health Organization, around 2.1 million people were living with HIV in South America in 2019. According to the UNAIDS, around 45,000 people are estimated to live with HIV/AIDS in Germany and around 700 people die annually from AIDS. An estimated of 101,600 people living with HIV in the United Kingdom (UK). According to the Chinese Center for Disease Control and Prevention, approximately 1.25 million people living with HIV/AIDS in China in 2019. India has the third largest HIV epidemic in the world, with 2.1 million people living with HIV in 2020. According to the World Health Organization (WHO), around 23.8 million African has HIV in Africa. Approximately 91% of the world's HIV-positive children live in Africa. More than one million adults and children die every year from HIV/AIDS in Africa. Further, rising government initiatives for HIV and raise awareness about diagnosis and management of HIV/AIDS is a key driving factor of the market. However, side effect and high cost of HIV drugs might hamper the market growth. Efavirenz is an anti-HIV drug that reduces the HIV virus in the body. Efavirenz slows down damage to the immune system and prevents the occurrence of AIDS. The side-effects of efavirenz occur in the brain. Clinical trials have shown that 14 to 50% of people who take efavirenz has developed side-effects at the beginning of few months, including insomnia, dizziness, vivid dreams and nightmares, abnormal thinking, impaired concentration, loss of memory, confusion, agitation, hallucinations, delusions, euphoria, and depression. Moreover, strategic alliance and collaboration between companies and government bodies for the development and supply of HIV drugs would provide lucrative opportunities for the market in coming years. 

Market Segmentation 

The global HIV drugs market is mainly classified based on type and application. Type is further segmented into Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, and HIV Integrase Strand Transfer Inhibitors. By application the market is divided into Hospital Pharmacies, Retail Pharmacies, and Others.  

Based on type, nucleoside reverse transcriptase inhibitors were dominating the HIV drugs market in 2020, owing to the rising demand for HIV nucleoside reverse transcriptase inhibitors for HIV patients. non-nucleoside reverse transcriptase inhibitors have shown significant growth in 2020 due to the rising awareness on HIV, rising investment for the development of non-nucleoside reverse transcriptase inhibitors, and increasing clinical studies on non-nucleoside reverse transcriptase inhibitors for the treatment of HIV patients. For instance, Merck has received the U.S. Food and Drug Administration (FDA) acceptance for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults. The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF). 

Regional Analysis 

Based on geography, the global HIV drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America was dominating the HIV drugs market in 2020, due to the rising incidence and prevalence of HIV cases, commercialization of regulatory approved HIV drugs, and partnership between companies to develop, commercialize, and supply HIV drugs in the North American market. For instance, Gilead Sciences, Inc. and Merck have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen to provide new treatment options for people living with HIV. 

Competitive landscape 

Key players operating in the HIV drugs industry include Boehringer Ingelheim, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck Group, Viatris Inc., Pfizer Inc., Cipla, Teva Pharmaceutical Industries Ltd., and AbbVie. 

The increasing pipeline products for HIV drugs, commercialization of new HIV drugs, rising investment for the development and commercialization of HIV drugs, rising awareness for the treatment of HIV, and increasing regulatory approval of HIV drugs are some of the strategies adopted by the major companies. For instance, on January 21, 2021, ViiV Healthcare has received the US Food and Drug Administration (FDA) approval for Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is available as a co-pack with two injectable medicines including ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy. 

HIV Drugs Market Key Segments: 

By Type 

• Multi-Class Combination Products 
• Nucleoside Reverse Transcriptase Inhibitors 
• Non-Nucleoside Reverse Transcriptase Inhibitors 
• Protease Inhibitors 
• Fusion Inhibitors 
• Entry Inhibitors - CCR5 Co-Receptor Antagonist 
• HIV Integrase Strand Transfer Inhibitors 

By Application 

• Hospital Pharmacies 
• Retail Pharmacies 
• Others 

Key Global HIV Drugs Industry Players 

• Boehringer Ingelheim 
• Bristol-Myers Squibb Company 
• F. Hoffmann-La Roche AG 
• Gilead Sciences, Inc. 
• GlaxoSmithKline plc 
• Johnson & Johnson 
• Merck Group 
• Viatris Inc. 
• Pfizer Inc. 
• Cipla 
• Teva Pharmaceutical Industries Ltd. 
• AbbVie 

What Report Provides 

• Full in-depth analysis of the parent Industry 
• Important changes in market and its dynamics 
• Segmentation details of the market 
• Former, on-going, and projected market analysis in terms of volume and value 
• Assessment of niche industry developments 
• Market share analysis 
• Key strategies of major players 
• Emerging segments and regional growth potential